The Effect Of Methylphenıdate Treatment On Neuroınflammatıon Levels In Chıldren Wıth Attentıon Defıcıt Hyperactıvıty Dısorder

Launched by ENES FARUK ALTUNKILIÇ · Jun 19, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how a common medication called methylphenidate, used to treat children with Attention Deficit Hyperactivity Disorder (ADHD), affects certain markers in the blood that are related to brain inflammation. The researchers want to see if starting this treatment changes levels of specific substances linked to inflammation in the brain over a period of three months. Understanding this could help explain how the medication works beyond just improving attention and behavior.

Children between the ages of 6 and 11 who have been diagnosed with ADHD and are about to begin or have just started methylphenidate treatment may be eligible to join. To participate, children should not have other psychiatric conditions, ongoing infections, or chronic illnesses, and they should not have used psychiatric medications before. If eligible, participants will have blood samples taken before starting the medication and again three months later to measure the inflammation markers. This study is not yet recruiting, but it aims to provide new insights into how ADHD treatment affects brain health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. According to DSM-5 TR, the participant must have a diagnosis of "Attention Deficit Hyperactivity Disorder" and have started/be planning to start routine methylphenidate treatment.
• • 2. The participant must be between 6 and 11 years of age.
• • 3. The participant must agree to participate in the study after being informed about it.
• Exclusion Criteria:
• • 1. The presence of a psychiatric disorder diagnosis other than Attention Deficit Hyperactivity Disorder
• • 2. Having a diagnosis of Attention Deficit Hyperactivity Disorder but not planning to start methylphenidate
• • 3. Being under 6 years of age or over 11 years of age
• • 4. Having organic brain damage, mental retardation, autism spectrum disorder, neurological disease, or a physical illness that affects neurocognitive functions
• • 5. History of alcohol and/or psychoactive substance use
• • 6. Presence of ongoing active infection, allergic disease, and chronic illness
• • 7. Previous use of psychiatric medication.
• • 8. Presence of chronic illness
• • 9. Regular use of medication